Lupin joins hands with TTP, acquires exclusive rights to develop inhalation products

0 138

Lupin, on Thursday, announced that its subsidiary Lupin inc. has entered into an agreement with TTP plc (The Technology Partnership plc) to acquire the exclusive worldwide rights to develop, manufacture, and commercialize inhalation products.

As a part of the agreement, the company will use TTP’s soft-mist inhalation technology platform. It is expected that, by using this technology, Lupin will provide healthcare professionals with alternative solutions for delivering affordable inhaled medicines to patients across the globe.

As per the release, ‘Lupin and TTP will jointly develop the device. Lupin will commercially manufacture the device through its network of in-house and external manufacturing locations. Lupin will also develop and manufacture formulations to be delivered through the device, obtain the necessary regulatory approvals, and commercialize the products globally.’

Commenting on the development Vinita Gupta, Global CEO, Lupin said, “Inhalation is a strategic pillar of Lupin’s growth story, as we strive to bring affordable medicines to patients across the globe. The partnership with TTP for SMI technology platform is a strategic addition to our broad Inhalation capabilities.”

“Lupin is excited to be partnering with TTP. The organizations will work together to develop products using TTP’s SMI technology that complement Lupin’s portfolio of complex inhalation products.”

Alok Sonig, CEO – US Generics & Global R&D Head, Lupin

Commenting on the development, Sam Hyde, Managing Director, TTP said, “We are excited to be partnering with Lupin to commercialize our SMI technology so that it can benefit patients suffering with chronic respiratory conditions. TTP has deep expertise in aerosol science, and we have been working with our clients for over 30 years in complex drug delivery device development – this partnership represents an exciting next step for us in this innovative area of respiratory drug delivery.”

Soft-mist inhalation (SMI) technology eliminates the need for propellants in the delivery of inhalation medications using a compact, portable hand-held inhaler device. Individual doses are given by a precision-engineered nozzle system that creates a slow-moving, long-lasting aerosol cloud.

Leave A Reply

Your email address will not be published.